Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Theratechnologies Inc T.TH

Alternate Symbol(s):  THTX

Theratechnologies Inc. is a Canada-based clinical-stage biopharmaceutical company. The Company is focused on the development and commercialization of therapies addressing unmet medical needs. It markets prescription products for people with human immunodeficiency viruses (HIV) in the United States. The Company's research pipeline focuses on specialized therapies addressing unmet medical needs in HIV, nonalcoholic steatohepatitis (NASH) and oncology. Its medicines include Trogarzo and EGRIFTA SV (tesamorelin for injection). Trogarzo (ibalizumab-uiyk) injection is a long-acting monoclonal antibody which binds to domain 2 of the CD4 T cell receptors. EGRIFTA SV (tesamorelin for injection) is approved in the United States for the reduction of excess abdominal fat in people with HIV who have lipodystrophy. Its portfolio includes Phase I clinical trial of sudocetaxel zendusortide (TH1902), a novel peptide-drug conjugate (PDC), in patients with advanced ovarian cancer.


TSX:TH - Post by User

Comment by SPCEO1on Sep 09, 2021 12:23pm
122 Views
Post# 33833901

RE:RE:Dose escalation

RE:RE:Dose escalationA couplle fo questions about this:

1.) When I counted out the 28 week estimate for the phase 1a length, it suggested it would end in the first week of October but you have them starting the highest dose then. What accounts for that difference or how did you come up with the first week of October being the last step of the trial?

2.) If the trial had reacched a MTD already, I thought we had concluded that THTX might not be obligated to announce that. So, is it possible the trial has already ceased and we just do not know that yet? 

jfm1330 wrote: So, in theory, we are into another cycle at a higher dose of TH1902 now, this is equivalent 2.4 times the MTD of docetaxel alone. It seems that the previous dose, at almost two times the MTD was of docetaxel alone, was not toxic enough to be the MTD of TH1902. All this is very good, in theory, still it is not a proof of concept. 

jfm1330 wrote: Then, if they get there, it would be 558.6 mg/m2 on September 7, and 742 mg/m2 on October 5. This would be a bit higherthan three times the MTD of free docetaxel, which is what they saw on rats in the preclinical.




<< Previous
Bullboard Posts
Next >>